Responses
Clinical/translational cancer immunotherapy
Original research
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.
